AMP-activated protein kinase activation ameliorates eicosanoid dysregulation in high-fat-induced kidney disease in mice.

AICAR adenosine 5′-monophosphate adenosine 5′-monophosphate-activated protein kinase chronic kidney disease high-fat diet obesity

Journal

Journal of lipid research
ISSN: 1539-7262
Titre abrégé: J Lipid Res
Pays: United States
ID NLM: 0376606

Informations de publication

Date de publication:
05 2019
Historique:
received: 26 07 2018
revised: 28 02 2019
pubmed: 14 3 2019
medline: 14 8 2020
entrez: 14 3 2019
Statut: ppublish

Résumé

High-fat diet (HFD) causes renal lipotoxicity that is ameliorated with AMP-activated protein kinase (AMPK) activation. Although bioactive eicosanoids increase with HFD and are essential in regulation of renal disease, their role in the inflammatory response to HFD-induced kidney disease and their modulation by AMPK activation remain unexplored. In a mouse model, we explored the effects of HFD on eicosanoid synthesis and the role of AMPK activation in ameliorating these changes. We used targeted lipidomic profiling with quantitative MS to determine PUFA and eicosanoid content in kidneys, urine, and renal arterial and venous circulation. HFD increased phospholipase expression as well as the total and free pro-inflammatory arachidonic acid (AA) and anti-inflammatory DHA in kidneys. Consistent with the parent PUFA levels, the AA- and DHA-derived lipoxygenase (LOX), cytochrome P450, and nonenzymatic degradation (NE) metabolites increased in kidneys with HFD, while EPA-derived LOX and NE metabolites decreased. Conversely, treatment with 5-aminoimidazole-4-carboxamide-1-β-D-furanosyl 5'-monophosphate (AICAR), an AMPK activator, reduced the free AA and DHA content and the DHA-derived metabolites in kidney. Interestingly, kidney and circulating AA, AA metabolites, EPA-derived LOX, and NE metabolites are increased with HFD; whereas, DHA metabolites are increased in kidney in contrast to their decreased circulating levels with HFD. Together, these changes showcase HFD-induced pro- and anti-inflammatory eicosanoid dysregulation and highlight the role of AMPK in correcting HFD-induced dysregulated eicosanoid pathways.

Identifiants

pubmed: 30862696
pii: S0022-2275(20)32264-1
doi: 10.1194/jlr.M088690
pmc: PMC6495162
pii:
doi:

Substances chimiques

Eicosanoids 0
AMP-Activated Protein Kinases EC 2.7.11.31

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

937-952

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK089503
Pays : United States
Organisme : NIDDK NIH HHS
ID : F30 DK094532
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK063491
Pays : United States
Organisme : NIDDK NIH HHS
ID : DP3 DK094352
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM020501
Pays : United States
Organisme : NHLBI NIH HHS
ID : K08 HL130944
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK105961
Pays : United States
Organisme : NIDDK NIH HHS
ID : R24 DK082841
Pays : United States

Informations de copyright

Copyright © 2019 Declèves et al.

Références

Cell Metab. 2015 Jul 7;22(1):125-37
pubmed: 26052006
J Anat. 2008 Jun;212(6):845-52
pubmed: 18510511
Biochim Biophys Acta. 2011 Nov;1811(11):648-56
pubmed: 21787881
J Am Soc Nephrol. 2007 Oct;18(10):2715-23
pubmed: 17855643
Nephrol Dial Transplant. 2020 Feb 1;35(2):303-312
pubmed: 30137494
Biochim Biophys Acta. 2016 Sep;1861(9 Pt A):1083-1095
pubmed: 27317983
Obesity (Silver Spring). 2015 Jul;23(7):1517-24
pubmed: 26054643
Trends Biochem Sci. 2004 Jan;29(1):18-24
pubmed: 14729328
FEBS Open Bio. 2018 Feb 26;8(4):664-670
pubmed: 29632818
J Pathol. 2018 Dec;246(4):470-484
pubmed: 30073645
Kidney Int Suppl. 1998 Sep;67:S88-94
pubmed: 9736261
Sci Rep. 2015 Nov 13;5:16474
pubmed: 26563579
J Clin Endocrinol Metab. 2017 Mar 1;102(3):810-821
pubmed: 27886515
Obes Res. 2004 Aug;12(8):1278-89
pubmed: 15340111
FASEB J. 2009 Jun;23(6):1946-57
pubmed: 19211925
Biochem J. 1994 Aug 1;301 ( Pt 3):721-6
pubmed: 8053897
Am J Kidney Dis. 2006 Nov;48(5):772-9
pubmed: 17059996
Kidney Int. 2014 Mar;85(3):611-23
pubmed: 24304883
Lipids. 2015 Oct;50(10):997-1008
pubmed: 26318121
Eur J Biochem. 1995 Apr 15;229(2):558-65
pubmed: 7744080
J Nutr Biochem. 2011 Jul;22(7):656-64
pubmed: 20965713
Obes Res Clin Pract. 2017 Jan - Feb;11(1):34-43
pubmed: 26964726
Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E175-87
pubmed: 20978234
Biochim Biophys Acta. 2011 Nov;1811(11):724-36
pubmed: 21689782
Prostaglandins Leukot Essent Fatty Acids. 2003 Feb;68(2):145-50
pubmed: 12538078
Curr Protoc Bioinformatics. 2016 Sep 07;55:14.10.1-14.10.91
pubmed: 27603023
Diabetes. 2013 Jun;62(6):1945-56
pubmed: 23349501
Curr Diabetes Rev. 2011 Jan;7(1):41-9
pubmed: 21067508
Exp Diabetes Res. 2012;2012:758614
pubmed: 22007192
Free Radic Biol Med. 2006 Jul 15;41(2):213-21
pubmed: 16814101
Prostaglandins Other Lipid Mediat. 2016 Dec;127:9-13
pubmed: 27913146
Diabetologia. 2017 Apr;60(4):729-739
pubmed: 28188334
Lipids. 1988 Nov;23(11):1059-63
pubmed: 3237005
NCHS Data Brief. 2015 Nov;(219):1-8
pubmed: 26633046
Curr Opin Clin Nutr Metab Care. 2011 Jul;14(4):347-53
pubmed: 21587068
J Biol Chem. 2005 Sep 16;280(37):32317-25
pubmed: 16046411
Beijing Da Xue Xue Bao Yi Xue Ban. 2006 Apr 18;38(2):170-5
pubmed: 16617360
PLoS One. 2015 Nov 13;10(11):e0142848
pubmed: 26565966
Am J Physiol Regul Integr Comp Physiol. 2005 Jan;288(1):R188-96
pubmed: 15345471
Hypertension. 2003 Oct;42(4):594-9
pubmed: 12939236
Molecules. 2014 Mar 17;19(3):3247-63
pubmed: 24642910
Kidney Int. 2001 Apr;59(4):1498-509
pubmed: 11260414
Postgrad Med J. 2009 Nov;85(1009):614-21
pubmed: 19892897
J Biol Chem. 2015 Oct 2;290(40):24484-94
pubmed: 26276392
J Hypertens. 2003 Mar;21(3):601-9
pubmed: 12640255
Metabolites. 2015 Dec 11;5(4):720-32
pubmed: 26690487
Int J Mol Med. 2013 Dec;32(6):1293-302
pubmed: 24068196
Am J Hypertens. 2005 Apr;18(4 Pt 1):530-7
pubmed: 15831364
Am J Kidney Dis. 2011 Feb;57(2):245-54
pubmed: 21251540
Kidney Int. 2014 May;85(5):1112-22
pubmed: 24352154
J Am Soc Nephrol. 2011 Oct;22(10):1846-55
pubmed: 21921143
J Biol Chem. 2015 Mar 13;290(11):6986-93
pubmed: 25632961
Biochim Biophys Acta. 2011 Jun;1811(6):409-17
pubmed: 21172452
J Clin Invest. 2008 May;118(5):1645-56
pubmed: 18431508
J Am Soc Nephrol. 2017 May;28(5):1534-1551
pubmed: 27932476
PLoS One. 2009 Dec 01;4(12):e8089
pubmed: 19956652
Prog Lipid Res. 2008 Mar;47(2):147-55
pubmed: 18198131
J Biol Chem. 2016 Oct 14;291(42):21848-21856
pubmed: 27551045
Exp Ther Med. 2017 Apr;13(4):1622-1629
pubmed: 28413519
PLoS One. 2015 Jul 10;10(7):e0132498
pubmed: 26162096
Clin Sci (Lond). 2004 Dec;107(6):561-70
pubmed: 15307815
J Lipid Res. 2010 Nov;51(11):3299-305
pubmed: 20671299
Nat Rev Nephrol. 2016 Aug;12(8):453-71
pubmed: 27263398
Lancet Diabetes Endocrinol. 2014 May;2(5):417-26
pubmed: 24795255
J Physiol. 2006 Jul 1;574(Pt 1):7-15
pubmed: 16644800

Auteurs

Anne-Emilie Declèves (AE)

Institute of Metabolomic Medicine University of California, San Diego, La Jolla, CA; Laboratory of Metabolic and Molecular Biochemistry Faculty of Medicine, Université of Mons, Mons, Belgium. Electronic address: anne-emilie.decleves@umons.ac.be.

Anna V Mathew (AV)

Division of Nephrology Department of Internal Medicine, University of Michigan, Ann Arbor, MI.

Aaron M Armando (AM)

Departments of Pharmacology, University of California, San Diego, La Jolla, CA.

Xianlin Han (X)

Barshop Institute of Aging, Department of Medicine University of Texas Health San Antonio, San Antonio, TX.

Edward A Dennis (EA)

Departments of Pharmacology, University of California, San Diego, La Jolla, CA; Chemistry and Biochemistry University of California, San Diego, La Jolla, CA.

Oswald Quehenberger (O)

Departments of Pharmacology, University of California, San Diego, La Jolla, CA; Medicine, University of California, San Diego, La Jolla, CA.

Kumar Sharma (K)

Institute of Metabolomic Medicine University of California, San Diego, La Jolla, CA; Center for Renal Precision Medicine, Division of Nephrology, Department of Medicine University of Texas Health San Antonio, San Antonio, TX.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH